Kenneth Whittington
Emergency Medicine · Hazlehurst, MSNPI 1679514863
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 494 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,721 and has fallen 71.0% since, to $500 in 2025. Among emergency medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 494 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Abbott$987
- Novartis$663
- Novo Nordisk$564
- Merck$477
- Lilly USA, LLC$395
- plus $4K from 27 others
What the payments were for
- Food & beverage$8,003100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 76 | $1,234 |
| Abbott | 53 | $987 |
| Novartis | 47 | $663 |
| Novo Nordisk | 37 | $564 |
| Merck | 31 | $477 |
| Lilly USA, LLC | 26 | $395 |
| Pfizer | 25 | $356 |
| Mylan Specialty L.p. | 15 | $341 |
| Bayer | 20 | $319 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $303 |
| GSK | 19 | $295 |
| Astellas Pharma US Inc | 17 | $260 |
| AbbVie(2 entities) | 15 | $251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $237 |
| Amgen | 13 | $233 |
| Sanofi-aventis U.S. LLC | 14 | $220 |
| Boehringer Ingelheim | 12 | $194 |
| Global Blood Therapeutics, Inc. | 7 | $172 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $130 |
| E.r. Squibb & Sons, L.L.C. | 7 | $101 |
| Kowa Pharmaceuticals America, Inc. | 4 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $55 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Biogen | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Boston Scientific | 1 | $12 |
| Corium, LLC | 1 | $8 |
How this compares
$8,023 in reported general payments places this provider in the 95th percentile of 443 emergency medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $66,349 |
| MounjaroTirzepatide | 44 | $43,496 |
| OzempicSemaglutide | 42 | $40,394 |
| LinzessLinaclotide | 44 | $40,018 |
| TradjentaLinagliptin | 33 | $33,878 |
| JanuviaSitagliptin Phosphate | 36 | $33,617 |
| JardianceEmpagliflozin | 25 | $30,708 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $29,970 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $27,555 |
| FarxigaDapagliflozin Propanediol | 20 | $20,431 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $19,115 |
| MyrbetriqMirabegron | 16 | $14,975 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $9,903 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $7,002 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 247 | $5,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $356 | $68,57279 claims |
| Boehringer IngelheimTradjenta, Jardiance | $194 | $64,58658 claims |
| MerckJanuvia, Janumet Xr | $477 | $43,51954 claims |
| Lilly USA, LLCMounjaro | $395 | $43,49644 claims |
| AbbVieLinzess, Synthroid | $251 | $41,03864 claims |
| Novo NordiskOzempic | $564 | $40,39442 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,234 | $39,54537 claims |
| GSKTrelegy Ellipta | $295 | $29,97041 claims |
| Astellas Pharma US IncMyrbetriq | $260 | $14,97516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 443 emergency medicine providers in Mississippi.
Other emergency medicine in Hazlehurst
- Robert WalkerHazlehurst$5K
- Stanley ThompsonSouthaven$466K
- Utsav NandiJackson$54K
- Richard SummersJackson$20K
- Damon DarseyJackson$11K
- Samuel Richardson IiiJackson$8K
- Joseph PongettiJackson$5K
- Salvador ArceoBrandon$5K
- Manuel OngCarthage$5K
- Jessica JonesJackson$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.